Morgan Stanley analyst Dara Mohsenian reiterates his Underweight rating on Clorox (CLX) shares despite the stock's recent underperfomance compared to peers such as Procter & Gamble (PG), Colgate-Palmolive (CL) and Church & Dwight (CHD) as he believes the company's decelerating topline growth, market share losses and lower gross margin expansion make the stock's current valuation compared to peers unwarranted. Though he is not yet revising his estimates, Mohsenian sees risk of downward earnings revisions if scanner trends continue to deteriorate, he tells investors. He maintains a $144 price target on Clorox shares.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Paramount (PARA)... To see the rest of the story go to thefly.com. See Story Here

Reports Q3 revenue $20.2B, consensus $20.41B. "We delivered solid sales and strong earnings growth in the third quarter despite multiple headwinds, enabling us to raise our EPS growth guidance and maintain our top-line outlook for the fiscal year," said Jon Moeller, Chairman of the Board, President and CEO. "We remain committed to our integrated strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority - across product performance, packaging, brand communication, retail execution and consumer and customer value - productivity, constructive disruption and an agile and accountable organization. We are increasing investments in superiority to drive market growth and sustain strong momentum. We have confidence this remains the right strategy to deliver balanced growth and value creation."